Ripretinib is a Small Molecule owned by Deciphera Pharmaceuticals, and is involved in 10 clinical trials, which were completed.

Ripretinib (Qinlock, DCC-2618) blocks cKIT mutated in a region called (exon 17) and the mutant D816V form of cKIT causative of mast cell leukemia and mastocytosis. The proto-oncogene c-Kit forms an active dimer that autophosphorylates itself and activates a signaling cascade that induces cell growth. PDGF and its receptors are implicated in tumorigenesis and angiogenesis. Thus, DCC-2618 acts on a mutant cKIT and mutant platelet derived growth factor receptor (PDGFR) alpha and inhibits tumor cell proliferation and angiogenesis.

The revenue for Ripretinib is expected to reach a total of $632m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Ripretinib NPV Report.

Ripretinib is originated and owned by Deciphera Pharmaceuticals. Zai Lab is the other company associated in development or marketing of Ripretinib.

Ripretinib Overview

Ripretinib (Qinlock) is a potent antineoplastic agent. It is formulated as tablets for oral route of administration. Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

Ripretinib (DCC-2618) was under development for the treatment of gastrointestinal stromal tumor (GIST), melanoma, anaplastic astrocytomas, glioblastoma multiforme, non-small cell lung cancer, glioma, germ cell tumors, penile cancer, soft tissue sarcoma, hematologic malignancy, systemic mastocytosis, solid tumor and mast cell leukemia. The drug candidate is a small molecule, administered through the oral route. It binds to mutant cKIT (including exons 14 and 17) and mutant platelet derived growth factor receptor alpha (PDGFRA). It is developed based on kinase inhibitor technology platform which provides the basis for the discovery and development of kinase switch pocket inhibitors. 

Zai Lab Overview

Zai Lab biopharmaceutical company that carries out drug development, discovery and commercializing therapies which address medical conditions with unmet needs in oncology. The company offering products pipeline includes Zejula Niraparib is a once-daily small molecule poly (ADP-ribose) polymerase 1/2inhibitor, Optune Tumor Treating Fields for cancer treatment, Qinlock Ripretinib and NUZYRA Omadacycline, a novel tetracycline-class antibacterial. The company market its products to the United States, Europe, Canada, Australia, Greater China and certain other countries and regions. Zai Lab is headquartered in Shanghai, China.

The company reported revenues of (US Dollars) US$144.3 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$49 million in FY2020. The operating loss of the company was US$700.1 million in FY2021, compared to an operating loss of US$301.8 million in FY2020. The net loss of the company was US$704.5 million in FY2021, compared to a net loss of US$268.9 million in FY2020. The company reported revenues of US$57.5 million for the third quarter ended September 2022, an increase of 19.4% over the previous quarter.

Quick View – Ripretinib

Report Segments
  • Innovator (NME)
Drug Name
  • Ripretinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.